For a slow-growing lymphoma that is not causing problems, treating straight away has not been shown to help people live longer, so the usual plan is regular checks and treatment later. It is the hardest thing in lymphoma to be told, and the evidence behind it is good.
What the choice is. Most follicular lymphoma is advanced by the time it is found, because it grows slowly and causes few symptoms. For someone with no symptoms, no organ problem and no fast-growing nodes, the options are to start treatment now or to be monitored and treated when the disease begins to cause trouble. Lymphoma Action calls the second one active monitoring, and lists the diseases it is used for: follicular lymphoma except grade 3B, the marginal zone lymphomas, Waldenstrom macroglobulinaemia, chronic lymphocytic leukaemia and small lymphocytic lymphoma, some mantle cell lymphoma, and nodular lymphocyte predominant Hodgkin lymphoma.
What is known about waiting. The randomised evidence is a British-led trial of 379 people with asymptomatic, non-bulky, advanced follicular lymphoma, reported by Ardeshna and colleagues in 2014. People given rituximab waited longer before needing chemotherapy or radiotherapy than people watched: at three years 88 per cent of the rituximab maintenance group had not needed new treatment, against 46 per cent of those watched. The long-term report in 2025, at a median follow-up of 14.7 years, found that 34 per cent of the people watched had still not started treatment at 15 years, and that their median time to a first new treatment was 5.6 years. Neither abstract gives overall survival, and the full texts could not be re-read on 17 November 2026; a 2026 pooled analysis of three studies and 1,590 patients found no statistically significant difference in overall survival between early rituximab and watching (hazard ratio 0.89, 95 per cent confidence interval 0.70 to 1.12). In other words, starting treatment earlier bought time to the next treatment and has not been shown to add years of life. Lymphoma Action lists the gains from waiting plainly: you avoid the side effects and the late effects for as long as possible, the full range of treatment is still open to you, your appointments are occasional rather than constant, and new treatments arrive while you wait.
What is known about the waiting itself. Lymphoma Action says monitoring means one to four check-ups a year, with a conversation about symptoms, an examination of the neck, armpits, groin and abdomen, and blood tests; a scan is not usually done unless the team suspects the lymphoma is growing, in order to avoid unnecessary radiation. Treatment is usually suggested when the marrow is affected and blood counts are falling, when an organ is affected, when nodes or the spleen grow quickly or appear in new places, when fever, night sweats and weight loss appear, or when symptoms become difficult to live with. Some people need treatment soon; some wait many years; some never need it.
What nobody can tell you. How long your own wait will be. Lymphoma Action says this varies a great deal and is hard to predict, and that follicular lymphoma transforms into a faster-growing lymphoma in 2 to 3 people in every 100 each year, which is why a change in symptoms is a reason to ring rather than to wait for the next appointment.
The part that is not medical. A person on active monitoring quoted on the Lymphoma Action page puts the difficulty exactly: "Active monitoring is counter-intuitive: 'I have cancer, but it's not being treated.' There is no physical battle, but there is a psychological challenge." The charity says some people find it helps to think of the lymphoma as a long-term condition to manage, that family and friends might also find the approach difficult to understand, and that many people feel anxious in the days or weeks before a check-up. Its helpline is free on 0808 808 5555, from 10am to 3pm on Monday to Friday, and is open to relatives as well as patients.
Showing the technology this term belongs to: Psycho-oncology and distress screening.
Shares Nodal marginal zone lymphoma, Splenic marginal zone lymphoma, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Waldenström macroglobulinaemia.
Shares Nodal marginal zone lymphoma, Splenic marginal zone lymphoma, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Marginal zone lymphoma.
Shares Watch and wait in lymphoma: when the right treatment is none yet, Watchful waiting, and how it differs from active surveillance, FLIPI, FLIPI2 and POD24 (follicular lymphoma risk), Follicular lymphoma.
Shares Nodal marginal zone lymphoma, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Marginal zone lymphoma, Follicular lymphoma.
Shares Waldenström macroglobulinaemia, Marginal zone lymphoma, Mantle cell lymphoma, Follicular lymphoma.
Shares Nodal marginal zone lymphoma, Splenic marginal zone lymphoma, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Waldenström macroglobulinaemia.
Shares Nodal marginal zone lymphoma, Splenic marginal zone lymphoma, Marginal zone lymphoma.
Shares FLIPI, FLIPI2 and POD24 (follicular lymphoma risk), Waldenström macroglobulinaemia, Marginal zone lymphoma, Follicular lymphoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/